NYSE:RMD - ResMed Stock Price, News, & Analysis

ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."

ResMed declared a quarterly dividend on Thursday, August 2nd. Stockholders of record on Thursday, August 16th will be paid a dividend of $0.37 per share on Thursday, September 20th. This represents a $1.48 dividend on an annualized basis and a dividend yield of 1.30%. The ex-dividend date of this dividend is Wednesday, August 15th. This is a positive change from ResMed's previous quarterly dividend of $0.35. View ResMed's Dividend History.

ResMed Inc. (NYSE:RMD) released its quarterly earnings data on Thursday, August, 2nd. The medical equipment provider reported $0.95 earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of $0.95. The medical equipment provider had revenue of $623.63 million for the quarter, compared to analyst estimates of $622.78 million. ResMed had a net margin of 13.49% and a return on equity of 24.74%. The business's revenue was up 12.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.77 earnings per share. View ResMed's Earnings History.

ResMed is scheduled to release their next quarterly earnings announcement on Thursday, October, 25th 2018. View Earnings Estimates for ResMed.

11 Wall Street analysts have issued twelve-month price targets for ResMed's stock. Their forecasts range from $55.00 to $90.00. On average, they expect ResMed's share price to reach $68.80 in the next twelve months. This suggests that the stock has a possible downside of 39.6%. View Analyst Price Targets for ResMed.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last year. There are currently 3 sell ratings, 5 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for ResMed.

Some companies that are related to ResMed include Boston Scientific (BSX), Baxter International (BAX), FRESENIUS SE &/S (FSNUY), ABIOMED (ABMD), Teleflex (TFX), DexCom (DXCM), Hill-Rom (HRC), Insulet (PODD), Haemonetics (HAE), ICU Medical (ICUI), Integra Lifesciences (IART), Penumbra (PEN), Globus Medical (GMED), Novocure (NVCR) and Cantel Medical (CMD).

News articles about RMD stock have trended somewhat positive on Friday, according to Accern Sentiment. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. ResMed earned a news and rumor sentiment score of 0.18 on Accern's scale. They also assigned media coverage about the medical equipment provider an impact score of 46.57 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term. View Recent Headlines for ResMed.

ResMed's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.67%), FMR LLC (5.66%), Baillie Gifford & Co. (3.38%), Northern Trust Corp (1.15%), Bank of New York Mellon Corp (1.14%) and Bank of New York Mellon Corp (1.14%). Company insiders that own ResMed stock include Brett Sandercock, Christopher G Roberts, David Pendarvis, Franz Kozich, Gary W Pace, James Hollingshead, John P Wareham, Jr Gregor K Emmert, Michael J Farrell, Peter C Farrell, Richard Mchale, Richard Sulpizio, Ronald R Taylor and Warren Russell Hawkins. View Institutional Ownership Trends for ResMed.

RMD stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Russell Investments Group Ltd., NN Investment Partners Holdings N.V., WINTON GROUP Ltd, Janus Henderson Group PLC, Bank of New York Mellon Corp, Bank of New York Mellon Corp and Baillie Gifford & Co.. Company insiders that have sold ResMed company stock in the last year include Brett Sandercock, David Pendarvis, Gary W Pace, James Hollingshead, John P Wareham, Peter C Farrell, Richard Mchale, Richard Sulpizio and Ronald R Taylor. View Insider Buying and Selling for ResMed.

RMD stock was acquired by a variety of institutional investors in the last quarter, including Los Angeles Capital Management & Equity Research Inc., Morgan Stanley, Canada Pension Plan Investment Board, Standard Life Aberdeen plc, Renaissance Technologies LLC, Schwab Charles Investment Management Inc., Capital Fund Management S.A. and Mackay Shields LLC. Company insiders that have bought ResMed stock in the last two years include Franz Kozich, Jr Gregor K Emmert and Warren Russell Hawkins. View Insider Buying and Selling for ResMed.

Shares of RMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of RMD stock can currently be purchased for approximately $113.83.

ResMed has a market capitalization of $16.07 billion and generates $2.34 billion in revenue each year. The medical equipment provider earns $315.58 million in net income (profit) each year or $3.53 on an earnings per share basis. ResMed employs 5,940 workers across the globe.

ResMed's mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The medical equipment provider can be reached via phone at 858-836-5000 or via email at [email protected]